Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells

Anti-androgen therapy with Enzalutamide (Enz) has been used as a therapy for castration resistant prostate cancer (CRPC) patients after development of resistance to chemotherapy with Docetaxel (Doc). The potential impacts of Doc-chemotherapy on the subsequent Enz treatment, however, remain unclear....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Aging (Albany NY)
Prif Awduron: Lin, Changyi, Chou, Fu-Ju, Lu, Jieyang, Lin, Wanying, Truong, Matthew, Tian, Hao, Sun, Yin, Luo, Jie, Yang, Rachel, Niu, Yuanjie, Nadal, Rosa, Antonarakis, Emmanuel S., Cordon-Cardo, Carlos, Sahasrabudhe, Deepak, Huang, Chi-Ping, Yeh, Shuyuan, Li, Gonghui, Chang, Chawnshang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals 2020
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7521536/
https://ncbi.nlm.nih.gov/pubmed/32920545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.103917
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg